Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)

Trial Profile

An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs MVA brachyury TRICOM vaccine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 17 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 May 2018 According to a Bavarian Nordic media release, results from this study are expected in H2, 2018.
    • 01 Mar 2018 Planned primary completion date changed from 2 Dec 2017 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top